Adjusted for cell proportions: TRUE IFX ADA IFX - ADA pooled enriched in B cells (II) (LI.M47.1) -MHC-TLR7-TLR8 cluster (LI.M146) enriched in B cells (I) (LI.M47.0) enriched in T cells (I) (LI.M7.0) enriched in antigen presentation (I) (LI.M71) enriched in NK cells (I) (LI.M7.2) -B cell surface signature (LI.S2) antiviral IFN signature (LI.M75) type I interferon response (LI.M127) -T cell activation (II) (LI.M7.3) -T cell activation (I) (LI.M7.1) -Effect size (AUC) enriched in B cells (III) (LI.M47.2) -0.5 enriched in antigen presentation (II) (LI.M95.0) -0.6 regulation of antigen presentation and immune response (LI.M5.0) -Gene module viral sensing & immunity; IRF2 targets network (II) (LI.M111.1) antigen processing and presentation (LI.M200) -T cell surface signature (LI.S0) -Direction of effect Down in PR enriched in B cells (VI) (LI.M69) -Not significant cell cycle and transcription (LI.M4.0) -Up in PR enriched in myeloid cells and monocytes (LI.M81) extracellular matrix, complement (LI.M140) enriched in monocytes (IV) (LI.M118.0) -TBA (LI.M105) extracellular matrix (II) (LI.M2.1) -TBA (LI.M114.0) -Monocyte surface signature (LI.S4) -TLR and inflammatory signaling (LI.M16) enriched in neutrophils (I) (LI.M37.1) enriched in monocytes (II) (LI.M11.0) immune activation - generic cluster (LI.M37.0) --log10(FDR)